Results 191 to 200 of about 3,046 (215)
Some of the next articles are maybe not open access.
Mavacamten for obstructive hypertrophic cardiomyopathy
PrescriberMavacamten (Camzyos) is a cardiac myosin inhibitor indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. This article discusses its efficacy, adverse effects and place in therapy.
openaire +1 more source
Mavacamten: treatment aspirations in hypertrophic cardiomyopathy
The Lancet, 2020Michael, Papadakis +2 more
openaire +2 more sources
Effect of Chronopharmacology and Food on in Vivo Pharmacokinetic Profile of Mavacamten
Bioanalysis, 2023Rajesh Sonti +2 more
exaly
Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China
JAMA Cardiology, 2023openaire +2 more sources
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
New England Journal of MedicineMilind Y. Desai +13 more
+4 more sources
MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY: EFFECTIVE, BUT AFFORDABLE?
Journal of the American College of Cardiology, 2023Shivani Hanchate +4 more
openaire +1 more source
Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy
Annals of Pharmacotherapy, 2023Charles M. White
exaly